WHIM Syndrome

FDA Grants Orphan Drug Designation to AUM302 for Neuroblastoma A global clinical-stage biotech company, AUM Biosciences, focused on discovering and developing precision oncology therapeutics, declared that the U.S. FDA has permitted Orphan Drug Designation for AUM302. For the treatment of neuroblastoma, AUM302 i...

WHIM Syndrome possessing limited cures paves the way toward evolving demand for novel treatment therapies. Moreover, the increasing prevalence and R&D activities drive the WHIM syndrome treatment market forward. As per DelveInsight’s latest WHIM Syndrome epidemiology report, there were approximately 180 diag...